Schellenberg Wittmer has advised Bioventure Club Deal Nine & Co KG on a Series B Financing Round of the Swiss Aphaia Companies, which are clinical stage pharma companies that have developed proprietary treatment methods targeting
Schellenberg Wittmer has advised Bioventure Club Deal Nine & Co KG on a Series B Financing Round of the Swiss Aphaia Companies, which are clinical stage pharma companies that have developed proprietary treatment methods targeting